Publication:
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.

No Thumbnail Available

Date

2021-02-13T00:00:00Z

Institution Authors

Authors

Sezer, Ahmet
Kilickap, Saadettin
Gümüş, Mahmut
Bondarenko, Igor
Özgüroğlu, Mustafa
Gogishvili, Miranda
Turk, HACI MEHMET
Cicin, Irfan
Bentsion, Dmitry
Gladkov, Oleg

Journal Title

Journal ISSN

Volume Title

Publisher

Research Projects

Organizational Units

Journal Issue

Metrikler

Search on Google Scholar

Abstract

Description

Keywords

Citation

Sezer A., Kilickap S., Gümüş M., Bondarenko I., Özgüroğlu M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.-, Lancet (London, England), cilt.397, ss.592-604, 2021
Page Views

0

File Downloads

0

Sustainable Development Goals